The financials
Kymera Therapeutics, Inc. by the numbers
Kymera Therapeutics, Inc. (KYMR) reported revenue of $65M in Q2 2026 (quarter ended June 30, 2026), up 466% from the same quarter a year earlier. That came with a gross margin of 0.0% and net loss of $61M. For the full year FY2025, revenue was $39M (−17% year on year) and net income −$311M.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $65M | $11M | +466% |
| Gross profit | $0 | $0 | n/a |
| Operating income | −$76M | −$85M | n/a |
| Net income | −$61M | −$77M | n/a |
| Diluted EPS | −$0.62 | −$0.95 | n/a |